Skip to main content

Table 1 Trends in RDT-determined diagnostic positivity (DP) at each cluster over time as different IRS treatments were applied

From: Incremental impact upon malaria transmission of supplementing pyrethroid-impregnated long-lasting insecticidal nets with indoor residual spraying using pyrethroids or the organophosphate, pirimiphos methyl

Cluster October 2010–March 2011 October 2011–March 2012 October 2012–March 2013
IRS treatment DP % (n/N) IRS treatment DP % (n/N) IRS treatment DP % (n/N)
1 None 24.7 (372/1508) None 9.5 (95/998) None 14.4 (150/1039)
2 None 20.9 (559/2676) Pirimiphosmethyl EC 8.5 (280/3292) None 11.9 (126/1061)
3 None 26.9 (809/3006) None 10.8 (436/4033) None 14.1 (282/2004)
4 Deltamethrin WG 33.2 (825/2489) Pirimiphosmethyl EC 5.9 (217/3708) Pirimiphosmethyl EC 10.8 (314/2908)
5 Deltamethrin WG 27.5 (396/1439) Pirimiphosmethyl EC 18.2 (624/3436) Pirimiphosmethyl EC 27.3 (456/1673)
6 Deltamethrin WG 11.9 (338/2845) Lambdacyhalothrin CS 5.2 (76/1457) Lambdacyhalothrin CS 3.8 (57/1505)
7 Deltamethrin WG 6.0 (144/2415) Lambdacyhalothrin CS 4.2 (130/3111) Lambdacyhalothrin CS 2.99 (33/1105)
8 None 55.7 (202/363) None 29.9 (974/3261) Pirimiphosmethyl CS 9.0 (209/2321)
9 None 36.4 (4/11) Pirimiphosmethyl EC 46.6 (684/1467) Pirimiphosmethyl CS 23.5 (366/1561)
10 None 50.7 (172/339) None 35.4 (444/1254) Pirimiphosmethyl CS 27.1 (363/1341)
11 None 51.3 (60/117) Pirimiphosmethyl EC 30.2 (941/3112) None 11.9 (300/2531)
12 None 61.9 (26/42) None 33.9 (514/1517) Pirimiphosmethyl CS 21.7 (246/1132)
13 None 60.0 (120/200) Pirimiphosmethyl EC 27 (5.033/1974) None 30.6 (666/2180)
14 None 52.4 (33/63) None 41.3 (786/1904) Pirimiphosmethyl CS 16.99 (221/1301)